Search

Your search keyword '"Mabuchi, Seiji"' showing total 669 results
Start Over Author "Mabuchi, Seiji"
669 results on '"Mabuchi, Seiji"'

7. Extraovarian seromucinous borderline tumor: Case report and literature review.

Author

Sakata, Mina, Mabuchi, Seiji, Maeda, Michihide, Nagata, Shigenori, Tanaka, Junichiro, and Kamiura, Shoji

Subjects
*TUMOR diagnosis, *HYSTERECTOMY, *PAPILLARY carcinoma, *RARE diseases, *POSTMENOPAUSE, *TUMOR markers, *TREATMENT effectiveness, *ENDOMETRIOSIS, *TUMOR antigens, TUMOR surgery, CERVIX uteri tumors
Abstract

Seromucinous borderline tumors (SMBT) are papillary neoplasms without invasive capabilities. Originally categorized as ovarian tumors, SMBT, being an endometriosis‐related tumor, can manifest beyond the ovaries. To date, only four cases of extraovarian SMBT have been documented in literature. In this report, we present our experience with the first case of SMBT in the uterine cervix, which exhibited highly elevated CA19‐9 levels. The patient, initially clinically diagnosed with cervical cancer, underwent treatment with radical hysterectomy and was later pathologically diagnosed with SMBT of the uterine cervix. While extraovarian SMBT, especially in the uterine cervix, is extremely rare, this condition should be considered in patients with cervical masses lacking pathological evidence of malignant disease but displaying elevated CA19‐9 levels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Laparoscopic Radical Hysterectomy

Author

Kobayashi, Eiji, Takiuchi, Tsuyoshi, Matsuzaki, Shinya, Matsumoto, Yuri, Kodama, Michiko, Hashimoto, Kae, Mabuchi, Seiji, Ueda, Yutaka, Sawada, Kenjiro, Tomimatu, Takuji, Yoshino, Kiyoshi, Kimura, Tadashi, Konishi, Ikuo, Series Editor, Katabuchi, Hidetaka, Series Editor, and Mikami, Mikio, editor

Published
2019
Full Text
View/download PDF

22. Relationship between Abnormal Placenta and Obstetric Outcomes: A Meta-Analysis

Author

Matsuzaki, Shinya, primary, Ueda, Yutaka, additional, Matsuzaki, Satoko, additional, Sakaguchi, Hitomi, additional, Kakuda, Mamoru, additional, Lee, Misooja, additional, Takemoto, Yuki, additional, Hayashida, Harue, additional, Maeda, Michihide, additional, Kakubari, Reisa, additional, Hisa, Tsuyoshi, additional, Mabuchi, Seiji, additional, and Kamiura, Shoji, additional

Published
2023
Full Text
View/download PDF

28. Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy

Author

Takekuma, Munetaka, Takahashi, Fumiaki, Mabuchi, Seiji, Kudaka, Wataru, Horie, Koji, Ikeda, Mariko, Shikama, Ayumi, Mitsuhashi, Akira, Nagao, Shoji, Suzuki, Shiro, Mizuno, Mika, Nishio, Shin, Tokunaga, Hideki, Ota, Yukinobu, Kasamatsu, Takahiro, Kitagawa, Ryo, Toita, Takafumi, Kobayashi, Hiroaki, Ishikawa, Mitsuya, and Yaegashi, Nobuo

Published
2020
Full Text
View/download PDF

30. Supplemental Table 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

Author

Kinose, Yasuto, primary, Sawada, Kenjiro, primary, Makino, Hiroshi, primary, Ogura, Tomonori, primary, Mizuno, Tomoko, primary, Suzuki, Noriko, primary, Fujikawa, Tomoyuki, primary, Morii, Eiichi, primary, Nakamura, Koji, primary, Sawada, Ikuko, primary, Toda, Aska, primary, Hashimoto, Kae, primary, Isobe, Aki, primary, Mabuchi, Seiji, primary, Ohta, Tsuyoshi, primary, Itai, Akiko, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

31. Supplemental Figure Legend from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

Author

Kinose, Yasuto, primary, Sawada, Kenjiro, primary, Makino, Hiroshi, primary, Ogura, Tomonori, primary, Mizuno, Tomoko, primary, Suzuki, Noriko, primary, Fujikawa, Tomoyuki, primary, Morii, Eiichi, primary, Nakamura, Koji, primary, Sawada, Ikuko, primary, Toda, Aska, primary, Hashimoto, Kae, primary, Isobe, Aki, primary, Mabuchi, Seiji, primary, Ohta, Tsuyoshi, primary, Itai, Akiko, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

32. Supplemental Figure 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

Author

Kinose, Yasuto, primary, Sawada, Kenjiro, primary, Makino, Hiroshi, primary, Ogura, Tomonori, primary, Mizuno, Tomoko, primary, Suzuki, Noriko, primary, Fujikawa, Tomoyuki, primary, Morii, Eiichi, primary, Nakamura, Koji, primary, Sawada, Ikuko, primary, Toda, Aska, primary, Hashimoto, Kae, primary, Isobe, Aki, primary, Mabuchi, Seiji, primary, Ohta, Tsuyoshi, primary, Itai, Akiko, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

33. Supplemental Table 2 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment

Author

Kinose, Yasuto, primary, Sawada, Kenjiro, primary, Makino, Hiroshi, primary, Ogura, Tomonori, primary, Mizuno, Tomoko, primary, Suzuki, Noriko, primary, Fujikawa, Tomoyuki, primary, Morii, Eiichi, primary, Nakamura, Koji, primary, Sawada, Ikuko, primary, Toda, Aska, primary, Hashimoto, Kae, primary, Isobe, Aki, primary, Mabuchi, Seiji, primary, Ohta, Tsuyoshi, primary, Itai, Akiko, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 1 - 6, Table 1 from Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells

Author

Nakamura, Koji, primary, Sawada, Kenjiro, primary, Kinose, Yasuto, primary, Yoshimura, Akihiko, primary, Toda, Aska, primary, Nakatsuka, Erika, primary, Hashimoto, Kae, primary, Mabuchi, Seiji, primary, Morishige, Ken-ichirou, primary, Kurachi, Hirohisa, primary, Lengyel, Ernst, primary, and Kimura, Tadashi, primary

Published
2023
Full Text
View/download PDF

45. Systematic Review of the Survival Outcomes of Neoadjuvant Chemotherapy in Women with Malignant Ovarian Germ Cell Tumors.

Author

Sakaguchi-Mukaida, Hitomi, Matsuzaki, Shinya, Ueda, Yutaka, Matsuzaki, Satoko, Kakuda, Mamoru, Lee, Misooja, Deguchi, Satoki, Sakata, Mina, Maeda, Michihide, Kakubari, Reisa, Hisa, Tsuyoshi, Mabuchi, Seiji, and Kamiura, Shoji

Subjects
GERM cell tumors, ONLINE information services, MEDICAL databases, OVARIAN tumors, CONFIDENCE intervals, CANCER chemotherapy, RETROSPECTIVE studies, TREATMENT effectiveness, COMPARATIVE studies, DESCRIPTIVE statistics, COMBINED modality therapy, MEDLINE
Abstract

Simple Summary: This systematic review was conducted using four public electronic databases (PubMed, Web of Science, Scopus, and the Cochrane Central Register of Controlled Trials) from the date of inception to 31 May 2023, and 10 original articles with information regarding neoadjuvant chemotherapy (NACT) for malignant ovarian germ cell tumors (MOGCT) were identified. The results of the meta-analysis showed that NACT was used in approximately 40% of advanced MOGCT cases, with a response rate of 95.8%. The uterine preservation rate was approximately 70%, and the cumulative resumed menstruation rate was 100% (n = 30). Four comparator studies evaluating NACT versus primary debulking surgery between the groups showed similar overall survival, disease-free survival, recurrence rate, and adverse event rate (grade 3–4) from chemotherapy. Although available data are limited and level I evidence is lacking, we believe that NACT may be feasible for advanced MOGCT. Further studies are required to confirm this study's results. Randomized clinical trials assessing the efficacy of neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer have predominantly included women with high-grade serous carcinomas. The response rate and oncological outcomes of NACT for malignant ovarian germ cell tumors (MOGCT) are poorly understood. This study aimed to examine the effects of NACT on women with MOGCT by conducting a systematic review of four public search engines. Fifteen studies were identified, and a further descriptive analysis was performed for 10 original articles. In those studies, most women were treated with a bleomycin, etoposide, and cisplatin regimen, and one to three cycles were used in most studies. Four studies comparing NACT and primary debulking surgery showed similar complete response rates (n = 2; pooled odds ratio [OR] 0.90, 95% confidence interval [CI] 0.15–5.27), comparable overall survival (n = 3; 87.0–100% versus 70.0–100%), disease-free survival (n = 3; 87.0–100% versus 70.0–100%), recurrence rate (n = 1; OR 3.50, 95%CI 0.38–32.50), and adverse events rate from chemotherapy between the groups. In conclusion, NACT may be considered for the management of MOGCT; however, possible candidates for NACT use and an ideal number of NACT cycles remain unknown. Further studies are warranted to validate the efficacy of NACT in advanced MOGCT patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results